House Commerce Committee Medicare Rx Group Revisiting Risk Distribution
Executive Summary
The House Energy & Commerce Medicare reform working group is revisiting the distribution of financial risk between private health plans and the federal government under a Medicare prescription drug plan.
You may also be interested in...
House Commerce Hearing May 3 To Kick Off User Fee Reauthorization Debate
Drug approval times will be one topic of interest at the House Energy & Commerce/Health Subcommittee's May 3 hearing kicking off the user fee reauthorization process, Commerce Committee Majority Counsel Brent Del Monte told the Food & Drug Law Institute conference April 18 in Washington, D.C.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials